152 related articles for article (PubMed ID: 20484616)
1. Pharmacokinetics of dexrazoxane in subjects with impaired kidney function.
Brier ME; Gaylor SK; McGovren JP; Glue P; Fang A; Aronoff GR
J Clin Pharmacol; 2011 May; 51(5):731-8. PubMed ID: 20484616
[TBL] [Abstract][Full Text] [Related]
2. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK
Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of anakinra in subjects with different levels of renal function.
Yang BB; Baughman S; Sullivan JT
Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
[TBL] [Abstract][Full Text] [Related]
6. Influence of severe renal impairment on the pharmacokinetics of clazosentan.
Bruderer S; Sasu B; Tsvitbaum N; Dingemanse J
J Clin Pharmacol; 2011 Mar; 51(3):413-21. PubMed ID: 20926750
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.
Ishizuka H; Yoshiba S; Yoshihara K; Okabe H
J Clin Pharmacol; 2011 Feb; 51(2):243-51. PubMed ID: 20197485
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
Hasinoff BB; Aoyama RG
Chirality; 1999; 11(4):286-90. PubMed ID: 10224655
[TBL] [Abstract][Full Text] [Related]
9. Relative plasma levels of the cardioprotective drug dexrazoxane and its two active ring-opened metabolites in the rat.
Hasinoff BB; Aoyama RG
Drug Metab Dispos; 1999 Feb; 27(2):265-8. PubMed ID: 9929514
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
12. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Tetef ML; Synold TW; Chow W; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Somlo G; Yen Y; Groshen S; Johnson K; Lenz HJ; Gandara D; Doroshow JH
Clin Cancer Res; 2001 Jun; 7(6):1569-76. PubMed ID: 11410492
[TBL] [Abstract][Full Text] [Related]
14. Tigecycline pharmacokinetics in subjects with various degrees of renal function.
Korth-Bradley JM; Troy SM; Matschke K; Muralidharan G; Fruncillo RJ; Speth JL; Raible DG
J Clin Pharmacol; 2012 Sep; 52(9):1379-87. PubMed ID: 21953572
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment.
Gupta SK; Kantesaria B; Glue P
Drug Discov Ther; 2013 Aug; 7(4):158-63. PubMed ID: 24071578
[TBL] [Abstract][Full Text] [Related]
16. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
18. Effect of renal function on the pharmacokinetics of palifermin.
Gillespie B; Zia-Amirhosseini P; Salfi M; Kakkar T; Wang J; Gupta S; Smith B; Robson R; Sullivan JT
J Clin Pharmacol; 2006 Dec; 46(12):1460-8. PubMed ID: 17101745
[TBL] [Abstract][Full Text] [Related]
19. Garenoxacin pharmacokinetics in subjects with renal impairment.
Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of pilocarpine in subjects with varying degrees of renal function.
St Peter JV; Lambrecht LJ; Gunderson BW; Andersen SA; Gallagher SC; Swan SK
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1470-5. PubMed ID: 11185668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
